×
About 976,673 results

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
https://clinicaltrials.gov/ct2/show/NCT01902173

Sep 24th, 2021 - PRIMARY OBJECTIVES: I. To assess the safety of dabrafenib mesylate (dabrafenib) in combination with uprosertib (GSK2141795) and select the optimal dose of GSK2141795 for the phase II portion in patients with BRAF mutant cancer. (Effective November 15, 2014, this trial will not proceed to the Phase II study of dabrafenib and GSK2141795, but will move to an evaluation of triple therapy). (Phase I...

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
https://clinicaltrials.gov/ct2/show/NCT02601937

Sep 24th, 2021 - This is a Phase I, open-label, dose escalation and dose expansion study with BID (suspension) and TID (tablet) oral dose of tazemetostat. Subjects will be screened for eligibility within 14 days of the planned first dose of tazemetostat. A treatment cycle will be 28 days. Response assessment will be evaluated after 8 weeks of treatment and subsequently every 8 weeks while on study. The study ha...

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
https://clinicaltrials.gov/ct2/show/NCT02601950

Sep 24th, 2021 - This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21 days of the planned date of the first dose of tazemetostat and enrolled into one of 8 cohorts: Cohort using tazemetostat 800 mg BID Cohort 1 (Closed for enrollment): MRT, RTK, ATRT, and selected tumors wi...

Metabolism and the Activity of the Autonomic Nervous System in Patients With Paroxystic Sympathetic Hyperactivity, PSH
https://clinicaltrials.gov/ct2/show/NCT03441009

Sep 24th, 2021 - See report: Honore H, Eggertsen K, Sondergaard S: A study into the feasibility of using HRV variables to guide treatment in patients with paroxystic sympathetic hyperactivity in a neurointensive step-down unit. NeuroRehabilitation 2019, 44(1):141-155.

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02610413

Sep 24th, 2021 - PRIMARY OBJECTIVES: I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of hypertension in patients from the clinical trial Eastern Cooperative Oncology Group (ECOG)-5103 (E5103). OUTLINE: Previously collected germline DNA samples are analyzed via whole exome sequencing.

Comparing Allograft to Autograft Bone in ACDF Surgeries
https://clinicaltrials.gov/ct2/show/NCT03518164

Sep 24th, 2021 - The study is a prospective, randomized multicenter trial. Approximately 200 subjects will be enrolled at 12 sites throughout the United States and Canada. Up to 250 subjects may be enrolled to account for screen failures. Rutgers, New Jersey Medical School is the coordinating center for the study. The purpose of this study is to determine whether there is an advantage to using autograft (bone m...

Nutritional Drink in Gastroparesis
https://clinicaltrials.gov/ct2/show/NCT03500354

Sep 24th, 2021 - Primary objective: To evaluate the safety and tolerability of the nutritional drink in gastroparesis patients. Secondary objective: To evaluate the efficacy of the nutritional drink in gastroparesis patients. Study Procedures This study will be a pilot, open-label, trial in gastroparesis patients. A total of 20 patients will be recruited from the gastroenterology gastroparesis clinic. If the vo...

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-s...
https://clinicaltrials.gov/ct2/show/NCT03425643

Sep 24th, 2021 - This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery [adjuvant phase] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are ...

Nurse-led Family and Network Consultations
https://clinicaltrials.gov/ct2/show/NCT03458312

Sep 24th, 2021 - Objectives To explore the feasibility and benefits of a 'Nurse-led Family and Network Consultation' (FNC) that seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side. To explore the impact of these nurse consultations on the nurses' perception of autonomy, self-esteem, and con...

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03570892

Sep 24th, 2021 - This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.

A Prospective Assessment of Opioid Utilization Post-operatively in Sports Orthopaedic Surgeries
https://clinicaltrials.gov/ct2/show/NCT03422211

Sep 24th, 2021 - 1, Consent patients undergoing sports orthopaedic surgery in clinic or in pre-operative holding area and also administer first questionnaire, opioid risk tool, and pain catastrophizing scale(research) 2. Sports orthopaedic surgery (standard of care) 3. Post-op pain control regimen (standard of care) 4. Call or email patient with questionnaire every day for a week followed by weekly for 7 more w...

BEhavioral EConomics for Oral Health iNnovation Trial
https://clinicaltrials.gov/ct2/show/NCT03576326

Sep 24th, 2021 - This Phase II stratified randomized prevention trial will assess the efficacy of a behavioral economic theory-based financial incentive drawing program versus a control regimen to promote early childhood caries (ECC) preventive health behaviors (toothbrushing performance) for young children of predominantly Latino parents/caregivers in Early Head Start (EHS) and day care center programs.

Passive Leg Raising - an Important Diagnostic Manoeuvre
https://clinicaltrials.gov/ct2/show/NCT03454802

Sep 24th, 2021 - See above

Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor
https://clinicaltrials.gov/ct2/show/NCT03558945

Sep 24th, 2021 - This research study is a Phase I clinical trial, which tests the safety and effect of personalized neoantigen vaccines for pancreatic tumors. It is known that pancreatic tumors have various mutations (changes in genetic material) that are specific to an individual patient and tumors. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cel...

Study of Sacituzumab Govitecan-hziy in Metastatic Urothelial Cancer
https://clinicaltrials.gov/ct2/show/NCT03547973

Sep 24th, 2021 - The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy in participants with metastatic urothelial cancer (mUC).

Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
https://clinicaltrials.gov/ct2/show/NCT03578198

Sep 24th, 2021 - Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined therapy of rituximab plus MG4101 in patients with indolent CD20-positive NHLs who has relapsed or refractory to prior chemotherapy or chemo-radiotherapy.

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02610426

Sep 24th, 2021 - PRIMARY OBJECTIVES: I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of congestive heart failure (CHF) in patients from the clinical trial ECOG-5103 (E5103). OUTLINE: Previously collected germline DNA samples are analyzed via whole exome sequencing.

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
https://clinicaltrials.gov/ct2/show/NCT03435380

Sep 24th, 2021 - The primary purpose of this study is to determine the impact of maximizing patient and primary care provider (PCP) activation on breast cancer surveillance rates among women previously treated with chest radiotherapy (RT) for a childhood cancer. This is an 18-month, 3-arm randomized controlled trial using a smartphone intervention with data being collected at baseline and 18-months through pati...

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03568929

Sep 24th, 2021 - The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).

Strategy Training for People With Aphasia After Stroke
https://clinicaltrials.gov/ct2/show/NCT03593876

Sep 24th, 2021 - This pilot study will use a descriptive case series design with repeated measures to assess the feasibility of an adapted form of strategy training for people with communication impairments after acute stroke. The investigators will recruit people with aphasia due to stroke admitted to the inpatient rehabilitation units and administer the adapted form of strategy training one session per day 5 ...